AstraZeneca to buy Canadian cancer specialist Fusion for $2.4bn

Britain ’s biggest drugmaker’s latest acquisition will help it to develop new radiotherapy treatmentsBusiness live – latest updatesBritain ’s biggest drugmaker, AstraZeneca, is to buy a Canadian cancer specialist focused on next-generation treatments for $2.4bn (£1.9bn), the latest in a string of acquisitions made to strengthen its portfolio of new medicines.The Anglo-Swedish company struck an agreement to acquire Fusion Pharmaceuticals, which is developing next-generation radioconjugates that offer an alternative to chemotherapy and radiotherapy. It has emerged as a new type of cancer treatment in recent years, and delivers a radioactive isotope directly to cancer cells through precise targeting using molecules such as antibodies, peptides or small molecules.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: AstraZeneca Pharmaceuticals industry Mergers and acquisitions Cancer research Medical research Science Business UK news Source Type: news